SCA
FLNA

SAC Capital Advisors’s Filana Therapeutics FLNA Stock Holding History

SAC Capital Advisors’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-1,642
Closed -$56K – 1944
2013
Q4 		$56K Buy
+1,642
New +$43.6K ﹤0.01% 1738

Other funds holding FLNA

VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
MSP
Madison Street Partners Denver, Colorado $3.05M AUM 5.94% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
SC
Sophrosyne Capital New York $11.5M AUM 17.82% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return

SAC Capital Advisors's FLNA Position: Q1 2014 in Review

SAC Capital Advisors sold out of Filana Therapeutics (FLNA) in Q1 2014, closing a stake of 1,642 shares — an estimated $56K sold.

SAC Capital Advisors first reported a position in FLNA in Q4 2013 and held it in 1 quarter. The position peaked at $56K in Q4 2013. 75 funds tracked by Wall St. Rank hold FLNA as of Q1 2014.

  • SAC Capital Advisors reported no remaining Filana Therapeutics position as of Q1 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 1,642 Filana Therapeutics shares in Q1 2014, an estimated $56K.
  • SAC Capital Advisors first reported a position in Filana Therapeutics in Q4 2013 and held it in 1 quarter.
  • SAC Capital Advisors's Filana Therapeutics position peaked at $56K in Q4 2013.
  • 75 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2014.

Based on SAC Capital Advisors's 13F filing for Q1 2014, filed 15 May 2014.